Market context
Follow the story. See which markets it affects. Explore the context.
Eli Lilly (LLY) posted a blowout Q2 with 27% EPS beat and 91% Mounjaro growth, raising full-year guidance. Not a directly tracked symbol, but as a major S&P 500 component, strong results provide mild…
Eli Lilly posted 48% revenue growth in Q2 2026, driven by MOUNJARO/ZEPBOUND sales of $14.9B, and raised full-year guidance. Strong obesity drug demand and pipeline progress signal continued sector st…
Lockheed Martin (LMT) posted a strong Q2 beat, record $230B backlog, and raised FY guidance, sending shares up over 10%. Analysts see further upside toward $700 by 2027, though LMT isn't a widely tra…